Selegiline monotherapy in the treatment of Parkinson's disease

Neurology

Volumn 47, Issue 6 SUPPL. 3, 1996, Pages

  Koller, William C ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; AMINE OXIDASE (FLAVIN CONTAINING); LEVODOPA; SELEGILINE;

ANXIETY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DYSKINESIA; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; NAUSEA; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SWEATING; VOMITING;

EID: 0029731213     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.6_suppl_3.196s     Document Type: Review

References (38)

1. Rosen JA. The effect of a monoamine oxidase inhibitor on the bradykinesia of human parkinsonism. In: Barbeau A, Brunette JR, eds. Progress in neurogenetics. Int Congr Series No 175. Amsterdam: Excerpta Medica Foundation, 1969:346-351.
2. Barbeau A, Sourkes TL, Murphy GF. Les catecholamines dans la maladie de Parkinson. In: De Ajuriaguerra J, ed. Monoamines et systeme nerveux central. Geneva: George 1962:247-262.
3. Horwitz D, Goldberg LI, Sjoerdsma A. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. J Lab Clin Med 1969; 56:747-753.
4. Hunter KR, Boakes AJ, Laurence DR, Stern GM. Monoamine oxidase inhibitors and L-dopa. BMJ 1970;3:388.
5. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17:1285-1297.
6. Glover V, Sandler M, Owen F, Riley RJ. Dopamine is a monoamine oxidase B substrate in man. Nature 1977;265:80-81.
7. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 1983;95:57-80.
8. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandler M, eds. Monoamine oxidase: new vistas. New York: Raven, 1972:393-408.
9. Bhatia M, Jain E, Matheshwan MC. Role of selegiline as initial monotherapy in early Parkinson's disease. J Assoc Physicians India 1994;42:30-32.
10. Allain H, Pollak P, Neukirch HC, and members of the French selegiline multicenter trial. Symptomatic effect of selegiline in de novo parkinsonian patients. Mov Disord 1993;8(suppl 1): 536-540.
11. Myllyla VV, Sotaniemic KA, Vuorincn JA, Heinonen EA. Selegiline in de novo parkinsonian patients: the Finnish study. Mov Disord 1993;8(suppl 1):541-544.
12. LeWitt PA, Segel SA, Misturu KL, Schork MA. Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibitors: comparison of selegiline and lazabemide. Clin Neuropharmacol 1993;16:332-337.
13. Ziv E, Achiron A, Gyaldelli R, Drecsler A, Melamed E. Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: a quantitative assessment. Clin Neuropharmacol 1993;16:54-60.
14. Csanda E, Tanczy M. Selegiline in the early and late phases of Parkinson's disease. J Neurotrauma 1987;25(suppl):105-113.
15. Elizan TS, Yahr MD, Moroe PA. Selegiline use to prevent progression of Parkinson's disease: experience in 22 de novo patients. Arch Neurol 1987;46:1275-1279.
16. Teravainen H. Selegiline in Parkinson's disease. Acta Neurol Scand 1990;81:333-336.
17. Parkinson's Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989; 46:1052-1060.
18. Parkinson's Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
19. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) in the natural history of Parkinson's disease. Science 1989;245: 519-522.
20. Birkmayer W, Knoll J, Riederer P, et al. Improvement of life expectancy due to L-deprenyl addition to madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 1985;64:113-127.
21. Knoll J. Extension of life span of rats by long term (-)deprenyl treatment. Mt Sinai J Med 1988;55:67-74.
22. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984;120:547-578.
23. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984;225:1480-1482.
24. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32-37.
25. Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanism? Neurology 1991;42(suppl 6):13-26.
26. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36.
27. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
28. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-677.
29. Tatton WG, Ju WYL, Holland DP, et al. Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
30. Tatton WG, Ju WYH, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promises for new approaches to neurological therapy. In: Olanow CW, Jenner P, Youdim MHB, eds. Neurodegeneration and prospects for neuroprotection in Parkinson's disease. London: Academic (in press).
31. + in vivo. Eur J Pharmacol 1993; 243:241-247.
32. Golbe L, Lieberman A, Muenter M. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;2:45-55.
33. Poewe W, Gerstenbrand F, Rawsmayer G. Experience with selegiline in the treatment of Parkinson's disease. Neural Transm 1982;25:131-135.
34. Lees A, for the Parkinson's Study Group. Comparison of the therapeutic effect and mortality of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-1607.
35. Parkinson's Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
36. Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology 1989;39: 109-111.
37. Chrisp P, Mammen GJ, Sorkin CM. Selegiline, a reverse of its pharmacology: symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1991;1:228-248.
38. Lieberman A. Selegiline as symptomatic treatment for Parkinson's disease. In: Lieberman A, Olanow CW, Youdim MBH, Tipton K, eds. Monamine oxidase inhibitors in neurological diseases. New York: Marcel Dekker, 1994:263-279.